Tarextumab

Drug Profile

Tarextumab

Alternative Names: Anti-Notch 2/3; Anti-Notch 2/3 monoclonal antibody; OMP-59R5; TRXT

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Notch-2 receptor antagonists; Notch-3 receptor antagonists; Stem cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 05 Oct 2016 OncoMed completes the phase Ib/II ALPINE trial in Pancreatic cancer (First-line therapy, Combination therapy, Late-stage disease) in USA (NCT01647828)
  • 30 Aug 2016 OncoMed completes enrolment in its phase II PINNACLE trial for Small cell lung cancer (Combination therapy, First line therapy, Late-stage disease)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top